TCIM
ESPR

TIAA CREF Investment Management’s Esperion Therapeutics ESPR Stock Holding History

TIAA CREF Investment Management’s Portfolio ESPR Stock Details ESPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		$1.77M Sell
43,977
-9,943
-18% -$446K ﹤0.01% 2060
2018
Q4 		$2.48M Sell
53,920
-2,427
-4% -$117K ﹤0.01% 1827
2018
Q3 		$2.5M Buy
56,347
+6,106
+12% +$280K ﹤0.01% 2010
2018
Q2 		$1.97M Buy
50,241
+10,941
+28% +$553K ﹤0.01% 2182
2018
Q1 		$2.84M Buy
39,300
+1,508
+4% +$111K ﹤0.01% 1907
2017
Q4 		$2.49M Sell
37,792
-4,462
-11% -$240K ﹤0.01% 2012
2017
Q3 		$2.12M Buy
42,254
+3,180
+8% +$153K ﹤0.01% 2135
2017
Q2 		$1.81M Buy
39,074
+1,148
+3% +$42.2K ﹤0.01% 2238
2017
Q1 		$1.34M Sell
37,926
-984
-3% -$22.5K ﹤0.01% 2365
2016
Q4 		$487K Sell
38,910
-6,395
-14% -$76.1K ﹤0.01% 2862
2016
Q3 		$627K Hold
45,305
– – ﹤0.01% 2762
2016
Q2 		$448K Buy
45,305
+2,370
+6% +$39.3K ﹤0.01% 2910
2016
Q1 		$726K Sell
42,935
-12,086
-22% -$194K ﹤0.01% 2634
2015
Q4 		$1.23M Sell
55,021
-575
-1% -$14.5K ﹤0.01% 2463
2015
Q3 		$1.31M Buy
55,596
+12,391
+29% +$778K ﹤0.01% 2399
2015
Q2 		$3.53M Buy
43,205
+19,662
+84% +$1.92M ﹤0.01% 1930
2015
Q1 		$2.18M Buy
23,543
+3,934
+20% +$254K ﹤0.01% 2169
2014
Q4 		$793K Sell
19,609
-86
-0.4% -$2.63K ﹤0.01% 2785
2014
Q3 		$482K Hold
19,695
– – ﹤0.01% 2982
2014
Q2 		$312K Buy
19,695
+3,237
+20% +$46.8K ﹤0.01% 3064
2014
Q1 		$249K Buy
16,458
+6,700
+69% +$104K ﹤0.01% 3059
2013
Q4 		$134K Hold
9,758
– – ﹤0.01% 3102
2013
Q3 		$184K Buy
+9,758
New +$164K ﹤0.01% 3058

Other funds holding ESPR

BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $16.4B AUM 55.44% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.17B AUM 92.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CS
Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

TIAA CREF Investment Management's ESPR Position: Q1 2019 in Review

TIAA CREF Investment Management reduced its Esperion Therapeutics (ESPR) stake by 18% in Q1 2019, selling an estimated $446K and leaving 43,977 shares worth $1.77M. The position accounts for ﹤0.01% of the portfolio, ranked #2060.

TIAA CREF Investment Management first reported a position in ESPR in Q3 2013 and has held it in 23 quarters since. The position peaked at $3.53M in Q2 2015. 163 funds tracked by Wall St. Rank hold ESPR as of Q1 2019.

  • TIAA CREF Investment Management held 43,977 shares of Esperion Therapeutics worth $1.77M as of Q1 2019.
  • TIAA CREF Investment Management sold 9,943 Esperion Therapeutics shares in Q1 2019, an estimated $446K.
  • Esperion Therapeutics made up ﹤0.01% of TIAA CREF Investment Management's portfolio in Q1 2019, its #2060 holding.
  • TIAA CREF Investment Management first reported a position in Esperion Therapeutics in Q3 2013 and has held it in 23 quarters since.
  • TIAA CREF Investment Management's Esperion Therapeutics position peaked at $3.53M in Q2 2015.
  • 163 funds tracked by Wall St. Rank held Esperion Therapeutics as of Q1 2019.

Based on TIAA CREF Investment Management's 13F filing for Q1 2019, filed 14 May 2019.